Skip to main navigation Skip to search Skip to main content

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

  • Mitchell G. Lawrence
  • , Daisuke Obinata
  • , Shahneen Sandhu
  • , Luke A. Selth
  • , Stephen Q. Wong
  • , Laura H. Porter
  • , Natalie Lister
  • , David Pook
  • , Carmel J. Pezaro
  • , David L. Goode
  • , Richard J. Rebello
  • , Ashlee K. Clark
  • , Melissa Papargiris
  • , Jenna Van Gramberg
  • , Adrienne R. Hanson
  • , Patricia Banks
  • , Hong Wang
  • , Birunthi Niranjan
  • , Shivakumar Keerthikumar
  • , Shelley Hedwards
    • Alisee Huglo, Rendong Yang, Christine Henzler, Yingming Li, Fernando Lopez-Campos, Elena Castro, Roxanne Toivanen, Arun Azad, Damien Bolton, Jeremy Goad, Jeremy Grummet, Laurence Harewood, John Kourambas, Nathan Lawrentschuk, Daniel Moon, Declan G. Murphy, Shomik Sengupta, Ross Snow, Heather Thorne, Catherine Mitchell, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Scott M. Dehm, Wayne D. Tilley, Richard B. Pearson, Ross D. Hannan, Mark Frydenberg, Luc Furic, Renea A. Taylor, Gail P. Risbridger*
*Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    104 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy'. Together they form a unique fingerprint.
    Sort by

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Biochemistry, Genetics and Molecular Biology